Design and analysis of lipoprotein tracer kinetics studies in humans

Journal of Lipid Research

Volumn 47, Issue 8, 2006, Pages 1607-1619

  Barrett, P Hugh R ^a   Chan, Dick C ^a   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Apolipoproteins; Compartment models; Kinetics analysis; Lipids; Modeling; Stable isotopes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; LEUCINE; LIPOPROTEIN; STABLE ISOTOPE; TRACER;

BLOOD SAMPLING; CHOLESTEROL METABOLISM; COMPARTMENT MODEL; EXPERIMENTAL DESIGN; HUMAN; KINETICS; LABELING INDEX; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MATHEMATICAL MODEL; METHODOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN ISOLATION; QUANTITATIVE ANALYSIS; REVIEW; SAMPLING; SIGNAL TRANSDUCTION; SIMULATION; BIOLOGICAL MODEL; BLOOD; COMPUTER SIMULATION; ISOTOPE LABELING; METABOLISM;

COMPUTER SIMULATION; HUMANS; ISOTOPE LABELING; KINETICS; LIPID METABOLISM; LIPOPROTEINS; MODELS, BIOLOGICAL;

EID: 33747145594     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R600017-JLR200     Document Type: Review

References (88)

1. Parhofer, K. G., and P. H. R. Barrett. 2006. What we have learned about VLDL and LDL metabolism from human kinetics studies. J. Lipid Res. 47: 1620-1630.
2. Rashid, S., B. W. Patterson, and G. F. Lewis. 2006. What have we learned about HDL metabolism from human kinetics studies? J. Lipid Res. 47: 1631-1642.
3. Marsh, J. B., F. K. Welty, A. H. Lichtenstein, S. Lamon-Fava, and E. J. Schaefer. 2002. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis. 162: 227-244.
4. Marsh, J. B., F. K. Welty, and E. J. Schaefer. 2000. Stable isotope turnover of apolipoproteins of high-density lipoproteins in humans. Curr. Opin. Lipidol. 11: 261-266.
5. Barrett, P. H. R., and G. F. Watts. 2003. Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions. Curr. Opin. Lipidol. 14: 61-68.
6. Chan, D. C., P. H. R. Barrett, and G. F. Watts. 2004. Lipoprotein transport in the metabolic syndrome. Part I. Methodological aspects of stable isotope kinetics studies. Clin. Sci. 107: 221-232.
7. Chan, D. C., P. H. R. Barrett, and G. F. Watts. 2006. New studies of lipoprotein kinetics in the metabolic syndrome. Curr. Opin. Lipidol. 17: 28-36.
8. Cohen, J. 1977. Statistical Power Analysis for the Behavioral Sciences. Academic Press, New York.
9. Jones-Wright, P. 2006. Guiding principles and regulations. In Responsible Research - A Guide for Coordinators. C. A. Fedor, P. A. Cola, and C. Pierre, editors. Remedica, London. 11-34.
10. Cohn, J. S., D. A. Wagner, S. D. Cohn, J. S. Millar, and E. J. Schaefer. 1990. Measurement of very low density and low density lipoprotein apolipoprotein (apo) B-100 and high density lipoprotein apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J. Clin. Invest. 85: 804-811.
11. Lichtenstein, A. H., D. L. Hachey, J. S. Millar, J. L. Jenner, L. Booth, J. Ordovas, and E. J. Schaefer. 1992. Measurement of human apolipoprotein B-48 and B-100 kinetics in triglyceride-rich lipoproteins using [5,5,5-2H3]leucine. J. Lipid Res. 33: 907-914.
12. Bosner, M. S., L. G. Lange, W. H. Stenson, and R. E. Ostlund. 1999. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J. Lipid Res. 40: 302-308.
13. McNamara, D. J. 1987. Effects of fat-modified diets on cholesterol and lipid metabolism. Annu. Rev. Nutr. 7: 273-290.
14. Grundy, S. M., and M. A. Denke. 1990. Dietary influences on serum lipids and lipoproteins. J. Lipid Res. 31: 1149-1172.
15. Schaefer, E. J. 2002. Lipoproteins, nutrition, and heart disease. Am. J. Clin. Nutr. 75: 191-212.
16. O'Connor, J., and I. McDermott. 1997. The Art of Systems Thinking. Thorsons, London.
17. Campbell, M. J. 2001. Statistics at Square Two. BMJ Books, London.
18. Godfrey-Smith, P. 2003. Theory and Reality: An Introduction to the Philosophy of Science. University of Chicago Press, Chicago, IL.
19. Gitlin, D., D. G. Cornwell, D. Nakasato, J. L. Oncley, W. L. Hughes, and C. A. Janeway. 1958. Studies on the metabolism of plasma lipoproteins in the necrotic syndrome. II. The lipoproteins. J. Clin. Invest. 37: 720-729.
20. Bilheimer, D. W., S. Eisenberg, and R. I. Levy. 1972. The metabolism of VLDL protein - preliminary in vitro and in vivo observations. Biochim. Biophys. Acta. 260: 212-221.
21. Cryer, D. R., T. Matsushima, J. B. Marsh, and J. A. Cortner. 1985. Direct measurement of apolipoprotein B synthesis in human very low density lipoprotein using stable isotopes and mass spectrometry. J. Lipid Res. 27: 508-516.
22. McFarlane, A. S. 1958. Efficient trace-labelling of proteins with iodine. Nature. 182: 53-130.
23. Ramakrishnan, R., Y. Arad, S. Wong, and H. N. Ginsberg. 1990. Nonuniform radiolabeling of VLDL apolipoprotein B: implications for the analysis of studies of the kinetics of the metabolism of lipoproteins containing apolipoprotein B. J. Lipid Res. 31: 1031-1042.
24. Patterson, B. W., and A. M. Lee. 1986. Self-association and phospholipid binding properties of iodinated apolipoprotein A-I. Biochemistry. 25: 4953-4957.
25. Beltz, W. F., Y. A. Kesäniemi, B. V. Howard, and S. M. Grundy. 1985. Development of an integrated model for analysis of the kinetics of apolipoprotein B in plasma very low density lipoproteins, intermediate density lipoproteins, and low density lipoproteins. J. Clin. Invest. 76: 575-585.
26. Schaefer, J. R., D. J. Rader, and H. B. Brewer, Jr. 1992. Investigation of lipoprotein kinetics using endogenous labeling with stable isotopes. Curr. Opin. Lipidol. 3: 227-232.
27. Lichtenstein, A. H., J. S. Cohn, D. L. Hachey, J. S. Millar, J. M. Ordovas, and E. J. Schaefer. 1990. Comparison of deuterated leucine, valine, and lysine in the measurement of human apolipoprotein A-I and B-100 kinetics. J. Lipid Res. 31: 1693-1701.
28. 3H-leucine tracer: its use in kinetics studies of plasma lipoproteins. Metabolism. 46: 333-342.
29. Patterson, B. W., D. L. Hachey, G. L. Cook, J. M. Amann, and P. D. Klein. 1991. Incorporation of a stable isotopically labeled amino acid into multiple human apolipoproteins. J. Lipid Res. 32: 1063-1072.
30. Berman, M. 1979. Kinetic analysis of turnover data. Prog. Biochem. Pharmacol. 15: 67-108.
31. Barrett, P. H. R., K. G. Parhofer, D. Bier, and G. Schonfeld. 1992. Postmenopausal estrogen and the metabolism of plasma lipoproteins. N. Engl. J. Med. 326: 954-955.
32. Foster, D. M., P. H. R. Barrett, C. Cobelli, G. Toffolo, and W. Beltz. 1993. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J. Lipid Res. 34: 2193-2205.
33. Demant, T., C. J. Packard, H. Demmelmair, P. Stewart, A. Bedynek, D. Bedford, D. Seidel, and J. Shepherd. 1996. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. Am. J. Physiol. 270: E1022-E1036.
34. Chan, D., G. F. Watts, P. H. R. Barrett, L. J. Beili, T. G. Redgrave, and T. A. Mori. 2002. Regulatory effects of HMGCoA reductase inhibitor and fish oils on apolipoprotein B100 kinetics in insulin resistant obese male subjects with dyslipidaemia. Diabetes. 51: 2377-2386.
35. Berman, M., S. M. Grundy, and B. V. Howard, editors. 1982. Lipoprotein Kinetics and Modelling. Academic Press, New York.
36. rd edition. Biomedware, Ann Arbor, MI.
37. Patterson, B. W., G. Zhao, and S. Klein. 1998. Improved accuracy and precision of gas chromatography/mass spectrometry measurements for metabolic tracers. Metabolism. 47: 706-712.
38. Dwyer, K. P., P. H. R. Barrett, D. Chan, J. I. Foo, G. F. Watts, and K. D. Croft. 2002. Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetics studies of lipoproteins. J. Lipid Res. 43: 344-349.
39. Egusa, G., D. W. Brady, S. M. Grundy, and B. V. Howard. 1983. Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein apolipoprotein B. J. Lipid Res. 24: 1261-1267.
40. 125I-labeled lipoproteins. J. Lipid Res. 19: 578-584.
41. Barrett, P. H. R., and D. M. Foster. 1998. Kinetic analysis of lipoprotein metabolism. In Lipoproteins in Health and Disease. D. J. Betteridge, D. R. Illingworth, and J. Shepherd, editors. Arnold, London. 523-529.
42. Fisher, E. R., L. A. Zech, W. R. Fisher, L. A. Zech, P. Bardalaye, G. Warmke, and M. Berman. 1980. The metabolism of apolipoprotein B in subjects with hypertriglyceridemia and polydisperse LDL. J. Lipid Res. 21: 760-774.
43. Parhofer, K. G., P. H. R. Barrett, and P. Schwandt. 1999. LDL apolipoprotein B metabolism: comparison of two methods to establish kinetics parameters. Atherosclerosis. 144: 159-166.
44. Beal, S. L., and L. B. Sheiner. 1982. Estimating population kinetics. Crit. Rev. Biomed. Eng. 8: 195-222.
45. Cobelli, C., A. Lepschy, and G. Romanin Jacur. 1979. Identifiability of compartmental systems and related structural properties. Math. Biosci. 44: 1-18.
46. Cobelli, C., and J. J. DiStefano III. 1990. Parameter and structural identifiability concepts and ambiguities: a critical review and analysis. Am. J. Physiol. 239: R7-R24.
47. Yates, J. W. T. 2006. Structural identifiability of physiologically based pharmacokinetics models. J. Pharmacokinet. Pharmacodyn. 33: 421-439.
48. Akaike, H. 1974. A new look at the Statistical Model Identification. IEEE Trans. Automat. Control. 19: 716-723.
49. nd edition. J. Bronzino, editor. CRC Press & IEEE Press, Boca Raton, FL. 159: 1-11.
50. Berman, M., and M. F. Weiss. 1978. The SAAM Manual. USPHS (NIH) Publication No. 78-180. Washington, DC, US Government Printing Office.
51. Barrett, P. H., B. M. Bell, C. Cobelli, H. Golde, A. Schumitzky, P. Vicini, and D. M. Foster. 1998. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetics studies. Metabolism. 47: 484-492.
52. Cobelli, C., and D. M. Foster. 1998. Compartmental models: theory and practice using the SAAM II software system. Adv. Exp. Med. Biol. 445: 79-101.
53. Barrett, P. H. R., and K. G. Parhofer. 1998. Low density lipoprotein apolipoprotein B metabolism following apheresis: simulation studies of mass changes and tracer kinetics. Metabolism. 47: 478-483.
54. Thompson, G. R., T. Spinks, A. Ranicar, and N. B. Myant. 1977. Non-steady state studies of low density lipoprotein turnover in familial hypercholesterolemia. Clin. Sci. Mol. Med. 52: 361-369.
55. 13C]leucine infusion in normal volunteers. Eur. J. Clin. Invest. 23: 602-614.
56. Cummings, M. H., G. F. Watts, A. M. Umpleby, T. R. Hennessy, R. Naoumova, B. M. Lavin, G. R. Thompson, and P. H. Sonksen. 1995. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia. 38: 959-967.
57. Bordin, P., O. A. Bodamer, S. Venkatesan, R. M. Gray, P. A. Bannister, and D. Halliday. 1998. Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males. Eur. J. Clin. Nutr. 52: 104-109.
58. Phair, R. D., M. G. Hammond, J. A. Bowden, M. Fried, W. R. Fisher, and M. Berman. 1975. A preliminary model for human lipoprotein metabolism in hyperlipoproteinemia. Fed. Proc. 34: 2263-2270.
59. Chan, D. C., G. F. Watts, T. G. Redgrave, T. A. Mori, and P. H. R. Barrett. 2002. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism. 29: 1041-1046.
60. Parhofer, K. G., P. Hugh, R. Barrett, D. M. Bier, and G. Schonfeld. 1991. Determination of kinetics parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J. Lipid Res. 32: 1311-1323.
61. Packard, C. J., A. Munro, A. R. Lorimer, A. M. Gotto, and J. Shepherd. 1984. Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J. Clin. Invest. 74: 2178-2192.
62. Adiels, M., C. Packard, M. J. Caslake, P. Stewart, A. Soro, J. Westerbacka, B. Wennberg, S. O. Olofsson, M. R. Taskinen, and J. Borén. 2005. A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J. Lipid Res. 46: 58-67.
63. Zech, L. A., S. M. Grundy, D. Steinberg, and M. Berman. 1979. Kinetic model for production and metabolism of very low density lipoprotein triglycerides. Evidence for a slow production pathway and results for normolipidemic subjects. J. Clin. Invest. 63: 1262-1273.
64. Watts, G. F., P. H. R. Barrett, J. Ji, A. P. Serone, D. C. Chan, K. D. Croft, F. Loehrer, and A. G. Johnson. 2003. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 52: 803-811.
65. Fisher, W. R., V. Venkatakrishnan, L. A. Zech, C. M. Hall, L. L. Kilgore, P. W. Stacpoole, M. R. Diffenderfer, K. E. Friday, A. E. Sumner, and J. B. Marsh. 1995. Kinetic evidence for both a fast and a slow secretory pathway for apolipoprotein A-I in humans. J. Lipid Res. 36: 1618-1628.
66. Cheung, M. C., and J. J. Albers. 1982. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J. Lipid Res. 23: 747-753.
67. Taskinen, M. R., J. Kahri, V. Koivisto, J. Shepherd, and C. J. Packard. 1992. Metabolism of HDL apolipoprotein A-I and A-II in type I (insulin-dependent) diabetes mellitus. Diabetologia. 35: 347-356.
68. Ji, J., G. F. Watts, A. G. Johnson, D. C. Chan, E. M. M. Ooi, K. A. Rye, A. P. Serone, and P. H. R. Barrett. 2006. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J. Clin. Endocrinol. Metab. 91: 973-979.
69. Zech, L. A., E. J. Schaefer, T. J. Bronzert, R. L. Aamodt, and H. B. Brewer, Jr. 1983. Metabolism of human apolipoproteins A-I and A-II: compartment models. J. Lipid Res. 24: 60-71.
70. Rader, D. J., G. Castro, L. A. Zech, J. C. Fruchart, and H. B. Brewer, Jr. 1991. In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I,A-II. J. Lipid Res. 32: 1849-1859.
71. Chetiveaux, M., K. Ouguerram, Y. Zair, P. Maugere, I. Falconi, H. Nazih, and M. Krempf. 2004. New model for kinetics studies of HDL metabolism in humans. Eur. J. Clin. Invest. 34: 262-267.
72. Chetiveaux, M., F. Lalanne, G. Lambert, Y. Zair, K. Ouguerram, and M. Krempf. 2006. Kinetics of prebeta1 HDL and alphaHDL in type II diabetic patients. Eur. J. Clin. Invest. 36: 29-34.
73. Shachter, N. S. 2001. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 12: 297-304.
74. Huff, M. W., N. H. Fidge, P. J. Nestel, T. Billington, and B. Watson. 1981. Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. J. Lipid Res. 22: 1235-1246.
75. Malmendier, C. L., J. F. Lontie, G. A. Grutman, and C. Delcroix. 1988. Metabolism of apolipoprotein C-III in normolipemic human subjects. Atherosclerosis. 69: 51-59.
76. 125I-labeled very low density lipoproteins using immunoaffinity chromatography. J. Lipid Res. 24: 1251-1260.
77. Cohn, J. S., M. Tremblay, R. Batal, H. Jacques, C. Rodriguez, G. Steiner, O. Mamer, and J. Davignon. 2004. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis. 177: 137-145.
78. Nguyen, M. N., D. C. Chan, K. P. Dwyer, P. Bolitho, G. F. Watts, and P. H. R. Barrett. 2006. Use of Intralipid for kinetics analysis of HDL apoC-III: evidence for a homogeneous kinetics pool of apoCIII in plasma. J. Lipid Res. 47: 1274-1280.
79. Mahley, R. W., and Y. Huang. 1999. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr. Opin. Lipidol. 10: 207-217.
80. Gregg, R. E., L. A. Zech, E. J. Schaefer, and H. B. Brewer, Jr. 1984. Apolipoprotein E metabolism in normolipidemic human subjects. J. Lipid Res. 25: 1167-1176.
81. Rubinstein, A., J. C. Gibson, H. N. Ginsberg, and V. W. Brown. 1986. In vitro metabolism of apolipoprotein E. Biochim. Biophys. Acta. 879: 355-361.
82. Millar, J. S., A. H. Lichtenstein, G. G. Dolnikowski, J. M. Ordovas, and E. J. Schaefer. 1998. Proposal of a multicompartmental model for use in the study of apolipoprotein E metabolism. Metabolism. 47: 922-928.
83. Batal, R., M. Tremblay, P. H. R. Barrett, H. Jacques, A. Fredenrich, O. Mamer, J. Davignon, and J. S. Cohn. 2000. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J. Lipid Res. 41: 706-718.
84. Cohn, J. S., R. Batal, M. Tremblay, H. Jacques, L. Veilleux, C. Rodriguez, O. Mamer, and J. Davignon. 2003. Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism. J. Lipid Res. 44: 1976-1983.
85. Patterson, B. W., B. Mittendorfer, N. Elias, R. Satyanarayana, and S. Klein. 2002. Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. J. Lipid Res. 43: 223-233.
86. Patterson, B. W. 2002. Methods for measuring lipid metabolism in vivo. Curr. Opin. Clin. Nutr. Metab. Care. 5: 475-479.
87. Schwartz, C. C., M. Berman, Z. R. Vlahcevic, and L. Swell. 1982. Multicompartmental analysis of cholesterol metabolism in man. Quantitative kinetics evaluation of precursor sources and turnover of high density lipoprotein cholesterol esters. J. Clin. Invest. 70: 863-876.
88. Ouguerram, K., M. Krempf, C. Maugeais, P. Maugere, D. Darmaun, and T. Magot. 2002. A new labelling approach using stable isotopes to study in vivo plasma cholesterol metabolism in humans. Metabolism. 51: 5-11.